Dataset Information

B1-SE_nonglyco_qstar

ABSTRACT: HUPO sample b1-SERUM non-glycopeptide on ABI QStar

INSTRUMENT(S): ABI QSTAR

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Others

SUBMITTER: Reto Ossola

PROVIDER: PAe000275 | PeptideAtlas |

REPOSITORIES: PeptideAtlas

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	PAe000275_308_search.params.tar.gz	Other
	PAe000275_308_searchdatabase_sequest.fasta	Fasta
	PAe000275_308_sequest.params	Other
	PAe000275_README	Other
	PAe000275_Search_Results_308_201106151142.properties	Other

Items per page:

1 - 5 of 10

Similar Datasets

Project description:Background: Abiraterone (Abi) is an androgen receptor signaling inhibitor that significantly improves patients' life expectancy in metastatic prostate cancer (PCa). Despite its beneficial effects, many patients have baseline or acquired resistance against Abi. Objective: To identify predictive serum biomarkers for Abi treatment. Design, setting, and participants: We performed a comparative proteome analysis on three Abi sensitive (LNCaPabl, LAPC4, DuCaP) and resistant (LNCaPabl-Abi, LAPC4-Abi, DuCaP-Abi) PCa cell lines using liquid chromatography tandem mass spectrometry (LC-MS/MS) technique. Two bioinformatic selection methods were applied to select the most promising candidate serum markers. Serum levels of selected proteins were assessed in samples of 100 Abi-treated patients with metastatic castration-resistant disease using ELISA. Moreover, FSCN1 serum concentrations were measured in samples of 69 Docetaxel (Doc) treated mCRPC patients. Outcome measurements and statistical analysis: Serum levels were correlated with patients‘ clinicopathological parameters and survival. Results and limitations: Our proteome analysis identified 68 significantly, at least two-fold upregulated proteins in Abi resistant cells. Using two filtering methods four proteins (AMACR, KLK2, FSCN1 and CTAG1A) were selected for ELISA analyses. We found high baseline FSCN1 serum levels to be significantly associated with poor survival in Abi-treated mCRPC patients. Moreover, the multivariable analysis revealed that higher ECOG status (>1) and high baseline FSCN1 serum levels (>10.22 ng/ml by ROC cut-off) were independently associated with worse survival in Abi-treated patients (p<0.001 and p=0.021, respectively). In contrast, no association was found between serum FSCN1 concentrations and overall survival in Doc-treated patients. Conclusions: Our analysis identified baseline FSCN1 serum levels to be independently associated with poor survival of Abi-treated, but not Doc-treated mCRPC patients, suggesting a therapy specific prognostic value for FSCN1. Patient summary: In this study, we identified serum FSCN1 as a marker that may help to predict PCa patients who derive less benefit from Abi but not Doc treatment.

Dataset Information

B1-SE_nonglyco_qstar

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets